NCT06374394 - A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above | Biotech Hunter

Enrollment

842

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

March 31, 2025

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSVPreF3 OA investigational vaccine

1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.

BIOLOGICAL

COVID-19 mRNA vaccine

1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.

Trial Locations (24)

2000

GSK Investigational Site, Antwerp

2650

GSK Investigational Site, Edegem

2800

GSK Investigational Site, Mechelen

9000

GSK Investigational Site, Ghent

9690

GSK Investigational Site, Kluisbergen

14609

GSK Investigational Site, Rochester

15006

GSK Investigational Site, A Coruña

23606

GSK Investigational Site, Newport News

27103

GSK Investigational Site, Winston-Salem

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28222

GSK Investigational Site, Madrid

28660

GSK Investigational Site, Boadilla Del Monte Madrid

29405

GSK Investigational Site, North Charleston

31406

GSK Investigational Site, Savannah

33134

GSK Investigational Site, Coral Gables

47714

GSK Investigational Site, Evansville

68134

GSK Investigational Site, Omaha

4818 CK

GSK Investigational Site, Breda

7512 KZ

GSK Investigational Site, Enschede

3584 BA

GSK Investigational Site, Utrecht

7207 AE

GSK Investigational Site, Zutphen

08023

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona